Also known as: m-Phenylenediamine, 4-13-00-00079, meta-Aminoaniline, Benzene, 1,3-diamino-, meta-Benzenediamine (+9 more)
CAS 108-45-2
1,3-Benzenediamine (CAS 108-45-2) is a chemical substance with GHS signal word Danger; key hazard signal: H341; H331; H311; H301; H319; H317; H400; H410. Key regulatory status: REACH registered, 6 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from ECHA CLP, EPA ToxValDB, EPA CPDat, AICIS, IARC, ECHA REACH, ILO ICSC, OSHA, EPA TRI.
1,3-Benzenediamine is prohibited in EU cosmetics but has active industrial GHS classifications (H341, H331, H311, H301, H319, H317, H400, H410).
CAS, identifiers, formula, and alternate names for the matched substance record.
Carcinogenic hazard classification from IARC monograph evaluations.
| Group | Meaning | Evaluated | Volume |
|---|---|---|---|
| Group 3 | Not classifiable | 1987 | 16, Sup 7 |
EU harmonized hazard classification, hazard statements, pictograms, and signal word.
| Hazard Class | H-Statements | Pictograms | Signal |
|---|---|---|---|
| Muta. 2; Acute Tox. 3 *; Acute Tox. 3 *; Acute Tox. 3 *; Eye Irrit. 2; Skin Sens. 1; Aquatic Acute 1; Aquatic Chronic 1 | H341; H331; H311; H301; H319; H317; H400; H410 | GHS08; GHS06; GHS09 | Danger |
International Chemical Safety Card hazard and exposure summary.
| Field | Value |
|---|---|
| Short-term Effects | The substance is irritating to the eyes and skin. The substance may cause effects on the kidneys and blood. This may result in renal failure and the formation of methaemoglobin. The effects may be delayed. Medical observation is indicated. |
| Long-term Effects | Repeated or prolonged contact may cause skin sensitization. The substance may have effects on the kidneys. This may result in renal failure. |
| Routes of Exposure | The substance can be absorbed into the body by inhalation of its vapour, through the skin and by ingestion. |
Occupational exposure limits from OSHA, NIOSH, and ACGIH rows.
| Agency | Metric | Value | ppm | mg/m3 | Skin |
|---|---|---|---|---|---|
| ACGIH | TWA | 0.1 mg/m³ [1988] | - | 0.1 | N |
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| CEDI | FDA | United States Food and Drug Administration (FDA) |
| Indirect additives food contact (10/2018) | FDA | United States Food and Drug Administration (FDA) |
| Europe; Food contact items; Toys and children's products | Danish EPA | Danish EPA |
| banned; Europe; Personal care | European Commission | CosIng |
| drinking_water; Europe; manufacturing; plastic_additive | Belgaqua | CPCat |
| banned; Europe; Personal care | European Commission | CosIng |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 0 | uL/min/10^6 cells | Clint | - | Human | NTP ICE adme parameters |
| =0.24 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB GESTIS DNEL |
| 0.49 | % | EC3 | Dermal | Mouse | NTP ICE skin sensitization |
| OE624J2447 | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 1 | unitless | GHS Classification | Ocular | Rabbit | NTP ICE eye irritation |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | unitless | IARC group | - | - | NTP ICE cancer |
| 0.35 | %/sec | Intensity | Ocular | - | NTP ICE eye irritation |
| =280 | mg/kg bw | LD50 | oral | Rat | NTP ICE acute oral |
| =650 | mg/kg bw | LD50 | oral | Rat | NTP ICE acute oral |
| =25 | mg/kg bw/day | LEL | oral | Cat | ECHA |
| >100 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| >=200 | mg/kg bw/day | LEL | injection | Cat | ECHA |
| =370 | mg/kg bw/day | LEL | injection | Rabbit | ECHA |
| =400 | mg/kg bw/day | LEL | injection | Mouse | ECHA |
| <=435 | mg/kg bw/day | LEL | injection | Cat | ECHA |
| <=440 | mg/kg bw/day | LEL | injection | Rabbit | ECHA |
| =450 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| =460 | mg/kg bw/day | LEL | injection | Rat | ECHA |
| =720 | mg/m3 | LEL | inhalation | Rat | ECHA |
| =1000 | mg/kg bw/day | LEL | oral | Rat | ECHA |
| =18 | mg/kg bw/day | LOAEL | oral | Rat | ToxValDB IRIS |
| 10 | s | Lag time | Ocular | - | NTP ICE eye irritation |
| 0 | unitless | Model Score | - | - | NTP ICE endocrine |
| =5 | mg/kg | NOAEL | - | rat | CIR Safety Assessment |
| =6 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =6 | mg/kg | NOAEL | dermal | rat | CIR Safety Assessment |
| =20 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =30 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =38.2 | mg/kg bw/day | NOAEL | oral | Mouse | ECHA |
| =41.8 | mg/kg bw/day | NOAEL | oral | Mouse | ECHA |
| =134 | mg/kg/day | NOAEL | oral | rat | CIR Safety Assessment |
| >=300 | mg/kg bw/day | NOAEL | oral | Rat | ECHA |
| =5 | mg/kg bw/day | NOEL | oral | Rat | ECHA |
| =6 | mg/kg/day | NOEL | oral | - | Regulatory source |
| 62 | % | Plateau level | Ocular | - | NTP ICE eye irritation |
| =0.006 | mg/kg bw/day | RfD | oral | Human | ToxValDB IRIS |
| =0.006 | mg/kg/day | RfD | oral | - | Regulatory source |
| =0.06 | mg/kg bw/day | RfD | oral | Human | ToxValDB RSL |
| 5 | mg/kg | developmental toxicity | - | rat | Regulatory source |
| 6 | mg/kg | repeated dose toxicity | dermal | rat | Regulatory source |
| 134 | mg/kg/day | repeated dose toxicity | oral | rat | Regulatory source |
Showing 42 of 42 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | m-phenylenediamine | 203-584-7 | ECHA overview → |
TRI hazard and reporting flags for the matched chemical.
| Chemical | Category | Flags |
|---|---|---|
| 1,3-Phenylenediamine | - | - |
Australian industrial chemicals inventory status and applicable conditions.
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
1,3-Benzenediamine (CAS 108-45-2) is classified under EU CLP Annex VI as Muta. 2; Acute Tox. 3 *; Acute Tox. 3 *; Acute Tox. 3 *; Eye Irrit. 2; Skin Sens. 1; Aquatic Acute 1; Aquatic Chronic 1 with signal word Danger. Hazard statements: H341; H331; H311; H301; H319; H317; H400; H410. Source: EU CLP Annex VI (ECHA).
1,3-Benzenediamine has 42 NOAEL studies in the database. The lowest reported value is 0 uL/min/10^6 cells in Human. Source: NTP ICE adme parameters.
1,3-Benzenediamine appears on 5 regulatory/inventory lists including CEDI, Indirect additives food contact (10/2018), Europe; Food contact items; Toys and children's products, and 2 more. Source: EPA CPDat.
1,3-Benzenediamine is classified by IARC as Group 3 — not classifiable as to its carcinogenicity to humans (evaluated 1987). Source: IARC Monographs on the Identification of Carcinogenic Hazards to Humans.
Occupational exposure limits for 1,3-Benzenediamine are set by ACGIH. 1 limit value from official agencies are documented in the database. Source: OSHA, NIOSH, ACGIH.
Yes, 1,3-Benzenediamine is also indexed as a cosmetic ingredient under the name m-Phenylenediamine. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from ECHA CLP Annex VI, EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, IARC Monographs, ECHA REACH, ILO/WHO ICSC, OSHA/NIOSH/ACGIH, EPA Toxics Release Inventory, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
1,3-Benzenediamine is prohibited in EU cosmetics but has active industrial GHS classifications (H341, H331, H311, H301, H319, H317, H400, H410).
1,3-Benzenediamine also appears in cosmetics, pharmaceutical databases.